Vudalimab
- Generic Name
- Vudalimab
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
Phase 2
Withdrawn
- Conditions
- Colorectal CancerColon CancerRectum Cancer
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05900648
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Phase 1
Recruiting
- Conditions
- Castration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyProcedure: FDG-Positron Emission TomographyProcedure: Magnetic Resonance ImagingProcedure: PSMA PET Scan
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 30
- Registration Number
- NCT05733351
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
Phase 2
- Conditions
- Metastatic Thyroid Gland Anaplastic CarcinomaLocally Advanced Thyroid Gland Anaplastic CarcinomaMetastatic Thyroid Gland Oncocytic Carcinoma
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 54
- Registration Number
- NCT05453799
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Phase 2
Suspended
- Conditions
- Peritoneal MesotheliomaHodgkin's LymphomaPleural MesotheliomaSmall Cell Lung CancerNeuroendocrine CarcinomasCervical CarcinomaMicrosatellite High CancersExtrapulmonary High Grade
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT05337735
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
XmAb20717 in Advanced Biliary Tract Cancers
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 27
- Registration Number
- NCT05297903
- Locations
- 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Phase 2
Active, not recruiting
- Conditions
- Cervical CarcinomaEndometrial CancerMetastatic Castration-Resistant Prostate Cancer (mCRPC)Clear Cell CarcinomaOvarian Cancer
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05032040
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath